Introduction

IGPNEA in partnership with Eli Lilly are delighted to announce a Masterclass in Diabetes for its members. The course shall consist of 10 modules delivered monthly via webinar accessible through the IGPNEA website. The course will be presented by experts in the field of diabetes, medical educators/diabetes nurse specialists. Each module shall attract a certificate of attendance. An application shall be made to NMBI for Category 1 approval for each module.

Click here to join the meeting: https://e.lilly/3TG0WJb

Modules

  • Module 1: Anatomy, Physiology & Aetiology of Diabetes  | Tuesday 24th January, 8pm – 9.30pm
  • Module 2: Complications of Diabetes  | Tuesday 24th February, 8pm – 9.30pm
  • Module 3: Diagnosis and monitoring of Diabetes  | Tuesday 28th March, 8pm – 9.30pm
  • Module 4: Practical management of Diabetes during illness; practical case studies | Tuesday 25th April, 8pm – 9.30pm
  • Module 5: Diabetes in the older patient and frailty  | Friday 12th May, IGPNEA National Conference, Portlaoise
  • Module 6: Overview of Type 2 Diabetes | Tuesday 30th May, 8pm – 9.30pm
  • Module 7: Thinking Beyond HbA1c  | Tuesday 27th June, 8pm – 9.30pm
  • Module 8: Oral Therapies for Type 2 Diabetes  | Tuesday 26th September, 8pm – 9.30pm
  • Module 9: Practical Use of Oral Therapies | Tuesday 24th October, 8pm – 9.30pm
  • Module 10: The relationship between cardiovascular, renal and metabolic systems in type 2 diabetes | Tuesday 28th November, 8pm – 9.30pm

MODULE ONE

Overview:

  • To recognise the pathophysiological development and progression of type 2 diabetes.
  • To discover the scale and scope of disease
  • To explore whether type 2 diabetes can be delayed or prevented

MODULE TWO

Overview:

  • Identifying short and long-term complications of diabetes
  • Exploring micro and macro vascular complications
  • Understanding monitoring guidelines for management of complications
  • Reviewing evidence-based outcomes

MODULE THREE

Objectives:

  • To be confident in determining an accurate diagnosis of type 2 diabetes.
  • To be aware of the standards of care for type 2 diabetes.
  • To identify the various methods required for the monitoring of type 2 diabetes.
  • To explore how to interpret blood glucose results, trends and patterns

MODULE FOUR

Objectives:

  • To be proactive in the prevention of illness, identifying those at high risk
  • To be active in preventing admissions to hospital where safe to do so
  • To understand the management of illness and acute complications
  • To be confident in management and the resolution of long-term outcomes

MODULE FIVE

Objectives:

  • To recognise the complexities and challenges of the increasing prevalence of diabetes within the older population
  • To develop an awareness of the available frailty assessment tools
  • To understand the implications of a diagnosis of frailty
  • To explore the setting and implementation of individualised targets for the older person with frailty

MODULE SIX

 Objectives:

  • To review the pathophysiology of type 2 diabetes
  • To understand the methods and criteria for diagnosing
    type 2 diabetes
  • To explore the impact of clinical inertia on patient outcomes and the importance of early treatment optimisation
  • To recognise the differences between compliance, adherence, and concordance and to understand the features of concordant patient consultations

MODULE SEVEN

Objectives:

  • Explore complications associated with type 2 diabetes
  • Consider the unmet clinical need related to cardiovascular morbidity and mortality in patients with type 2 diabetes
  • Understand how clinical guidance for type 2 diabetes has
    been updated to reflect the results of positive cardiovascular outcome trials
  • Reflect on the goals of treatment and individualised care for patients with type 2 diabetes

MODULE EIGHT

Objectives:

  • Discuss the considerations when choosing a treatment to meet the needs and circumstances of individual adult patients with type 2 diabetes
  • Review the standard oral therapies used in the treatment of
    type 2 diabetes: metformin, sulphonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors and oral GLP-1 RAs
  • Understand the sites of action for the different oral drug classes and be aware of the prescribing considerations including renal function and hepatic disease
  • Recognise the need to consider therapy specific factors and the individual patient’s circumstances when choosing between different
    oral therapies

MODULE NINE

Objectives:

  • To recall the different considerations when choosing oral treatments for patients with type 2 diabetes
  • To explore the need for individualised treatment targets and goals, and the impact that this has on choosing the right treatment, for the right patient, at the right time
  • To use case studies to bring theory to life

MODULE TEN

Objectives:

  • Explore the interconnected relationship between conditions of the CRM system across type 2 diabetes
  • Understand the wider impact and increased risks associated with having one or more conditions affecting the CRM system
  • Consider the unmet clinical need related to CRM morbidity and mortality in patients with type 2 diabetes
  • Understand how clinical guidance for type 2 diabetes has been updated to reflect the results of positive cardiovascular outcome trials
  • Reflect on the overall goals of treatment and individualised care for patients with type 2 diabetes